innovative platform technology

Innovative Technology Platform

Entera's innovative technology enables oral drug delivery of large molecules

27163516 pills

Pipeline of Drug Development

Entera conducts clinical trials of three oral drugs based on a proven active compound

27163516 brain green

Experienced Management Team

The managers of Entera have more than 50 years of experience in drug development

August 5, 2013 - Entera's drug candidate for osteoporosis will be tried for treating hypoparathyroidism, a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biologic activity. Entera has submitted an application to the ethics committee in England for ethical approval to conduct a trial at the Norfolk and Norwich University Hospital. The trial is expected to be 4 months long and will include 10 patients.